Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.

Oncotarget - 8 Mar 2016

Li Juan, Pan Qianying, Rowan Patrick D, Trotter Timothy N, Peker Deniz, Regal Kellie M, Javed Amjad, Suva Larry J, Yang Yang

Abstract excerpt

Bone dissemination and bone disease occur in approximately 80% of patients with multiple myeloma (MM) and are a major cause of patient mortality. We previously demonstrated that MM cell-derived heparanase (HPSE) is a major driver of MM dissemination to and progression in new bone sites. However the mechanism(s) by which HPSE promotes MM progression remains unclear. In the present study, we investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Cell Growth Processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronidase

Share to Heparin

Share to Heterografts

Share to Mesenchymal Stem Cells

Share to Multiple Myeloma

Share to Vimentin

Source

Open in PubMed Open full text

Identifiers

PMID: 26849235
DOI: 10.18632/oncotarget.7170
PMCID: PMC4905474

Genes

HPSE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.PMID 26849235Read ↗

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatinsSemantic proximity Read ↗

Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.Semantic proximity Read ↗

MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting HeparanaseSemantic proximity Read ↗

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaSemantic proximity Read ↗

Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.Semantic proximity Read ↗

CXCL7 plays a crucial role in facilitating extramedullary invasion and osteolytic damage in multiple myelomaSemantic proximity Read ↗

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional ActivationSemantic proximity Read ↗

Myeloma cell–derived Runx2 promotes myeloma progression in boneSemantic proximity Read ↗

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myelomaSemantic proximity Read ↗

Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factorSemantic proximity Read ↗

Extracellular Vesicles Enhance Multiple Myeloma Metastatic DisseminationSemantic proximity Read ↗

Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.